Stock AnalizProtagonist Therapeutics, Inc PTGX
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
Protagonist Therapeutics, Inc (PTGX) is a healthcare company listed in the US with a market value of about $8.5B. In fiscal year 2025 it had revenue of $46M and net income of -$130M, a net margin of -282.8%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a P/E of 27.8, a price to free cash flow of 78.3, 5-year revenue growth of 10% a year, a 5-year average ROIC of -22%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.
Score: 1.4 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $46M | $434M | $60M | $27M | $27M | $29M | $231000 | $31M | $20M | — |
| Net income | -$130M | $275M | -$79M | -$127M | -$126M | -$66M | -$77M | -$39M | -$37M | -$37M |
| Free cash flow | $56M | $183M | -$71M | -$109M | -$109M | -$73M | -$42M | -$50M | $3M | -$30M |
| EPS (diluted) | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 | $-1.92 | $-2.98 | $-1.74 | $-2.09 | $-5.80 |
| Net margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | -231.1% | -33414.3% | -125.9% | -184.2% | — |
| ROIC | -20.0% | 36.3% | -27.7% | -59.9% | -41.1% | -17.8% | -82.3% | -36.8% | -31.4% | -37.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $182.36, 39% above the current price; targets range from $151.00 to $225.00; the consensus rating is “Strong buy”; expected EPS is $5.09 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Protagonist Therapeutics’s P/E ratio?
About 27.8, based on the last twelve months of diluted earnings per share (forward P/E about 380.0).
Is Protagonist Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Protagonist Therapeutics pay a dividend?
Not currently.
Is Protagonist Therapeutics a good stock to buy?
We do not give buy or sell advice. Protagonist Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.